Siegel, R. L., Miller, Okay. D., Wagle, N. S. & Jemal, A. Most cancers statistics, 2023. CA Most cancers J. Clin. 73(1), 17–48 (2023).
Rebello, R. J. et al. Prostate most cancers. Nat. Rev. Dis. Primers. 7(1), 9 (2021).
Mottet, N. et al. EAU-ESTRO-SIOG tips on prostate most cancers. Half 1: Screening, analysis, and native therapy with healing intent. Eur. Urol. 71(4), 618–629 (2017).
Litwin, M. S. & Tan, H. J. The analysis and therapy of prostate most cancers: A overview. JAMA. 317(24), 2532–2542 (2017).
Gosein, M. A. et al. Biparametric MRI previous to radical radiation remedy for prostate most cancers in a caribbean inhabitants: Implications for danger group stratification and therapy. Radiol. Imaging Most cancers. 2(4), e200007 (2020).
Ahdoot, M. et al. MRI-targeted, systematic, and mixed biopsy for prostate most cancers analysis. N. Engl. J. Med. 382(10), 917–928 (2020).
Chang, A. J., Autio, Okay. A., Roach, M. third. & Scher, H. I. Excessive-risk prostate cancer-classification and remedy. Nat. Rev. Clin. Oncol. 11(6), 308–323 (2014).
Helgstrand, J. T. et al. Diagnostic traits of deadly prostate most cancers. Eur. J. Most cancers. 84, 18–26 (2017).
Eastham, J. A. et al. Clinically localized prostate most cancers: AUA/ASTRO guideline, Half I: Introduction, danger evaluation, staging, and risk-based administration. J. Urol. 208(1), 10–18 (2022).
Mohler, J. L. et al. Prostate most cancers, Model 2.2019, NCCN medical follow tips in oncology. J. Natl. Compr. Most cancers Netw. 17(5), 479–505 (2019).
Preisser, F. et al. Intermediate-risk prostate most cancers: Stratification and administration. Eur. Urol. Oncol. 3(3), 270–280 (2020).
Alarcon-Zendejas, A. P. et al. The promising position of recent molecular biomarkers in prostate most cancers: From coding and non-coding genes to synthetic intelligence approaches. Prostate Most cancers Prostatic Dis. 25(3), 431–443 (2022).
Eggener, S. E. et al. Molecular biomarkers in localized prostate most cancers: ASCO guideline. J. Clin. Oncol. 38(13), 1474–1494 (2020).
Fornaro, M. et al. Cloning of the gene encoding Trop-2, a cell-surface glycoprotein expressed by human carcinomas. Int. J. Most cancers. 62(5), 610–618 (1995).
Hsu, E. C. et al. Trop2 is a driver of metastatic prostate most cancers with neuroendocrine phenotype through PARP1. Proc. Natl. Acad. Sci. USA 117(4), 2032–2042 (2020).
Goldstein, A. S. et al. Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell traits. Proc. Natl. Acad. Sci. USA 105(52), 20882–20887 (2008).
Shen, M., Liu, S. & Stoyanova, T. The position of Trop2 in prostate most cancers: An oncogene, biomarker, and therapeutic goal. Am. J. Clin. Exp. Urol. 9(1), 73–87 (2021).
Stoyanova, T. et al. Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal through beta-catenin signaling. Genes Dev. 26(20), 2271–2285 (2012).
Hawley, S. et al. A mannequin for the design and development of a useful resource for the validation of prognostic prostate most cancers biomarkers: The Canary Prostate Most cancers Tissue Microarray. Adv. Anat. Pathol. 20(1), 39–44 (2013).
Jeon, Y., Jo, U., Hong, J., Gong, G. & Lee, H. J. Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast most cancers. BMC Most cancers. 22(1), 1014 (2022).
Went, P. T. et al. Frequent EpCam protein expression in human carcinomas. Hum. Pathol. 35(1), 122–128 (2004).
Shimizu, T. et al. First-in-human, part I dose-escalation and dose-expansion examine of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung most cancers: TROPION-PanTumor01. J. Clin. Oncol. 41(29), 4678–4687 (2023).
Dum, D. et al. Trophoblast cell floor antigen 2 expression in human tumors: A tissue microarray examine on 18,563 tumors. Pathobiology. 89(4), 245–258 (2022).
Ohmachi, T. et al. Medical significance of TROP2 expression in colorectal most cancers. Clin. Most cancers Res. 12(10), 3057–3063 (2006).
Bignotti, E. et al. Trop-2 overexpression as an impartial marker for poor general survival in ovarian carcinoma sufferers. Eur. J. Most cancers. 46(5), 944–953 (2010).
Bardia, A. et al. Sacituzumab govitecan in metastatic triple-negative breast most cancers. N. Engl. J. Med. 384(16), 1529–1541 (2021).
Tagawa, S. T. et al. TROPHY-U-01: A part II open-label examine of sacituzumab govitecan in sufferers with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J. Clin. Oncol. 39(22), 2474–2485 (2021).
Rugo, H. S. et al. Sacituzumab govitecan in hormone receptor-positive/human epidermal development issue receptor 2-negative metastatic breast most cancers. J. Clin. Oncol. 40(29), 3365–3376 (2022).
Rugo, H. S. et al. General survival with sacituzumab govitecan in hormone receptor-positive and human epidermal development issue receptor 2-negative metastatic breast most cancers (TROPiCS-02): A randomised, open-label, multicentre, part 3 trial. Lancet. 402(10411), 1423–1433 (2023).
Sperger, J. M. et al. Expression and therapeutic concentrating on of TROP-2 in treatment-resistant prostate most cancers. Clin. Most cancers Res. 29(12), 2324–2335 (2023).
Bardia, A. et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for sufferers with epithelial most cancers: Remaining security and efficacy outcomes from the part I/II IMMU-132-01 basket trial. Ann. Oncol. 32(6), 746–756 (2021).
Cooperberg, M. R., Broering, J. M. & Carroll, P. R. Time traits and native variation in major therapy of localized prostate most cancers. J. Clin. Oncol. 28(7), 1117–1123 (2010).
Rice, M. A. & Stoyanova, T. Biomarkers for analysis and prognosis of prostate Most cancers. In Prostatectomy (ed. Genadiev, T.) (InTechOpen, 2018).
D’Amico, A. V. et al. Biochemical end result after radical prostatectomy, exterior beam radiation remedy, or interstitial radiation remedy for clinically localized prostate most cancers. JAMA. 280(11), 969–974 (1998).
Cooperberg, M. R., Hilton, J. F. & Carroll, P. R. The CAPRA-S rating: An easy device for improved prediction of outcomes after radical prostatectomy. Most cancers. 117(22), 5039–5046 (2011).
Becerra, M. F., Atluri, V. S., Bhattu, A. S. & Punnen, S. Serum and urine biomarkers for detecting clinically important prostate most cancers. Urol. Oncol. 39(10), 686–690 (2021).
Poulos, C. Okay., Daggy, J. Okay. & Cheng, L. Preoperative prediction of Gleason grade in radical prostatectomy specimens: The affect of various Gleason grades from a number of constructive biopsy websites. Mod. Pathol. 18(2), 228–234 (2005).
Terada, N. et al. Prognostic and predictive biomarkers in prostate most cancers: Newest proof and medical implications. Ther. Adv. Med. Oncol. 9(8), 565–573 (2017).
Tomlins, S. A. et al. Urine TMPRSS2:ERG Plus PCA3 for individualized prostate most cancers danger evaluation. Eur. Urol. 70(1), 45–53 (2016).
